Status:
COMPLETED
Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF
Lead Sponsor:
Nova Scotia Health Authority
Collaborating Sponsors:
Nova Scotia Health Research Foundation
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Atrial fibrillation (AF) is a very common arrhythmia causing many symptoms resulting in numerous hospitalizations. Catheter ablation is a technique that has evolved significantly to improve symptomati...
Detailed Description
Background: Atrial fibrillation (AF) is the most common sustained arrhythmia and is associated with significant morbidity, necessitating treatment. Radiofrequency ablation for atrial fibrillation/flut...
Eligibility Criteria
Inclusion
- Documented systolic blood pressure greater than or equal to 130 mmHg
- Undergoing planned catheter ablation for persistent AF (lasting \> 7 days and \< 365 days or requiring electrical or chemical cardioversion) OR High burden paroxysmal AF \> 6 months (greater than or equal to 3 symptomatic episdes in past 6 months and refractory or inteolerant to at least 1 class 1 or 3 antiarrhythmic)
Exclusion
- Permanent atrial fibrillation
- Contraindication to Accupril or any other ACE-I
- Women of child-bearing potential
- Life expectancy less than 1 year
- Less than 18 years of age
- Unable to give informed consent
- Known moderate to several renal dysfunction (eGFR \< 30 ml/min/1.73m2)
- Prior AF catheter ablation
Key Trial Info
Start Date :
December 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
184 Patients enrolled
Trial Details
Trial ID
NCT00438113
Start Date
December 1 2009
End Date
September 1 2016
Last Update
June 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
QE II Health Sciences Centre
Halifax, Nova Scotia, Canada, B3H 3A7